Adma Biologics (ADMA) Cash from Operations (2011 - 2025)

Adma Biologics has reported Cash from Operations for 13 years, with the latest figure at 35639000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Operations fell 29.03% year-over-year to 35639000.0; the trailing twelve-month figure through Dec 2025 stood at 50396000.0 (down 57.53% YoY), and the FY2025 full-year result was 50396000.0, down 57.53% from the prior year.
• Cash from Operations for Q4 2025 stood at 35639000.0, up from 13293000.0 in the prior quarter.
• The five-year high for Cash from Operations was 50216000.0 in Q4 2024, with the low at 33465250.0 in Q4 2021.
• Historically, Cash from Operations has averaged 299550.0 across 5 years, with a median of 6719029.0 in 2022.
• Annual changes were most pronounced in 2024 — Cash from Operations soared 853.36% — and 2025, when it plunged 787.06%.
• Adma Biologics' Cash from Operations stood at 33465250.0 in 2021, then jumped by 77.95% to 7379058.0 in 2022, then jumped by 338.47% to 17597000.0 in 2023, then soared by 185.37% to 50216000.0 in 2024, then retreated by 29.03% to 35639000.0 in 2025.
• The last three Cash from Operations figures came in at 35639000.0 (Q4 2025), 13293000.0 (Q3 2025), and 21139000.0 (Q2 2025), per Business Quant data.